The overall incidence of hepatitis induced by immunotherapies has been reportedly low ~2–15%, and CTLA4 inhibitors have been reported to be associated with more cases of immune-mediated hepatitis (IH) than PD1/PDL1 inhibitors (49). Here, CD274 is linked to hepatitis A virus infection.